UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~August~~September 2111, 2025

KALVISTA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-36830	20-0915291
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or Other Jurisdictionof Incorporation)	(CommissionFile Number)	(IRS EmployerIdentification No.)

55 Cambridge Parkway Suite 901E
200 Crossing Boulevard
Cambridge, Massachusetts		02142
Framingham, Massachusetts		01702
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 857 999-0075

55 Cambridge Parkway

Suite 901E

Cambridge, Massachusetts 02142

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	KALV	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8 2.0102 ~~Other~~Results ~~Events~~of Operations and Financial Condition.

On September 11, 2025, KalVista Pharmaceuticals, Inc. (the “Company”) ~~has~~reported ~~set~~its ~~June 18,~~financial ~~2026~~results asfor the ~~date~~fiscal ofquarter ~~the~~ended ~~Company’s~~July 31, ~~2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”)~~2025. ~~The~~A ~~time~~copy ~~and location~~ of the ~~Annual~~press ~~Meeting~~release ~~will~~issued beby ~~set forth in~~ the Company’s ~~definitive~~is ~~proxy~~furnished ~~statement~~as ~~for~~Exhibit ~~the~~99.1 ~~2026 Annual Meeting~~ to bethis ~~filed with the Securities and Exchange Commission prior to the 2026 Annual Meeting~~report.

~~Since~~The ~~the~~information ~~date~~furnished ofwith ~~the~~Item ~~2026~~2.02 ~~Annual~~of ~~Meeting~~this ~~has~~report, ~~changed~~including byExhibit ~~more~~99.1, ~~than~~shall 30not ~~days~~be ~~from~~deemed ~~the~~“filed” ~~date~~for purposes of ~~the~~Section 18 ~~Company’s 2025 Annual Meeting~~ of ~~Stockholders, in accordance with Rule 14a-8 under~~ the Securities Exchange Act of 1934, as amended (the “Exchange Act”), ~~stockholder~~or ~~proposals~~otherwise subject to ~~be considered for inclusion in~~ the ~~proxy~~liabilities ~~materials~~of ~~for~~that ~~the~~section, ~~2026~~nor ~~Annual~~shall ~~Meeting~~it ~~must~~ be ~~submitted~~deemed inincorporated ~~writing~~ by ~~January 6,~~reference ~~2026,~~into toany ~~the~~other ~~Company’s~~filing ~~Corporate~~under ~~Secretary~~the atExchange 55Act ~~Cambridge~~or ~~Parkway,~~under ~~Suite~~the ~~901E,~~Securities ~~Cambridge,~~Act ~~Massachusetts~~of ~~02142~~1933, ~~which~~as ~~the~~amended, ~~Company~~except ~~believes~~as isexpressly aset ~~reasonable~~forth ~~time~~by ~~before~~specific itreference ~~begins~~in tosuch ~~print~~a ~~and send its proxy materials for the 2026 Annual Meeting~~filing.

Pursuant to the Company’s Amended and Restated Bylaws (the “Bylaws”), in order for a stockholder to present a proposal for the 2026 Annual Meeting, other than proposals to be included in the proxy statement as described above, or to nominate a director, stockholders must give notice on or before August 31, 2025, the 10th day after the date of this Current Report on Form 8-K announcing the date of the 2026 Annual MeetingItem 9.01 ~~Stockholders~~Financial ~~are~~Statements ~~also advised to review the Bylaws, which contain additional requirements about advance notice of stockholder proposals~~ and ~~director nominations~~Exhibits.

In addition to complying with the procedures of the Bylaws, including the notice deadlines set forth above and therein, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees, other than the Company’s nominees, must also comply with the additional requirements of Rule 14a-19 under the Exchange Act. (d) Exhibits


Exhibit Number		Description

99.1		Press release dated September 11, 2025

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

KALVISTA PHARMACEUTICALS, INC.

Date: August 21, 2025

/s/ Brian Piekos

Date: September 11, 2025

/s/ Benjamin L. Palleiko

Brian Piekos

Benjamin L. PalleikoChief Executive Officer

Chief Financial Officer (Principal Financial and Accounting Officer)

Filing Compare · KalVista Pharmaceuticals, Inc.